NESIRITIDE STUDY RESULTS REPORTED

Investigators reported results of a Scios-sponsored pilot trial that included information about the safety of the heart failure drug nesiritide on postoperative renal function and clinical outcomes in heart failure patients who required coronary artery bypass graft surgery using cardiopulmonary bypass.

Nesiritide is indicated for the intravenous treatment of patients with acutely decompensated congestive heart failure who have dyspnea at rest or with minimal activity.